Chief Executive Officer and Vice Chairman Yun Ung-seop of Ildong Pharmaceutical will be promoted to chairman of the Ildong Pharmaceutical Group. Chief Executive Officer and Vice Chairman Park Dae-chang of Ildong Holdoings, the holding company, has been appointed chairman.
Ildong Pharmaceutical Group said on the 31st that it carried out executive appointments effective Jan. 1 next year.
Yun Ung-seop, the third-generation member of the founding family of Ildong Pharmaceutical Group, joined Ildong Pharmaceutical in 2005 and built diverse hands-on and management experience through roles in strategic planning, PI (process innovation), and the corporate planning office. After becoming president and CEO of Ildong Pharmaceutical in 2014, in 2016 Yun reorganized the company's business structure and sought management stabilization through a shift to a holding-company system.
The group is pursuing the cultivation and diversification of the pharmaceuticals and healthcare sectors and is focusing on securing competitiveness in new drug research and development (R&D). The company is pushing ahead with new drug projects including a glucagon-like peptide (GLP)-1 obesity treatment, a P-CAB peptic ulcer treatment, and a PARP-inhibitor targeted anticancer drug.
Park Dae-chang, CEO and chairman of Ildong Holdoings, joined Ildong Pharmaceutical in 1978 and gained broad experience across key areas including production, sales, planning, strategy, and procurement. A licensed pharmacist by background, Park has strong expertise and a deep understanding of the industry. Starting as head of the Anseong plant in 2003, from 2007 Park served as head of production overseeing both the Cheongju plant and Anseong, responsible for the supply chain spanning active ingredients and finished drug manufacturing and control as well as logistics. Since 2018, Park has been with Ildong Holdoings and in 2021 became CEO, leading group operations such as affiliate management and support.